Physician Awareness and Utilization of Food and Drug Administration (FDA)-Approved Labeling for Pharmacogenomic Testing Information
We surveyed 10,303 United States physicians on where they obtain pharmacogenomic testing information. Thirty-nine percent indicated that they obtained this from drug labeling. Factors positively associated with this response included older age, postgraduate instruction, using other information sourc...
Main Authors: | Felix W. Frueh, Eric J. Stanek, Christopher L. Sanders |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2013-06-01
|
Series: | Journal of Personalized Medicine |
Subjects: | |
Online Access: | http://www.mdpi.com/2075-4426/3/2/111 |
Similar Items
-
Pharmacogenomic Biomarkers in US FDA-Approved Drug Labels (2000–2020)
by: Jeeyun A. Kim, et al.
Published: (2021-03-01) -
Physicians’ Knowledge, Attitude, and Experience of Pharmacogenomic Testing in China
by: Tong Jia, et al.
Published: (2022-12-01) -
ADME Gene-Related Pharmacogenomic Labeling of FDA-Approved Drugs: Comparison with Clinical Pharmacogenetics Implementation Consortium (CPIC) Evidence Levels
by: Subrata Deb, et al.
Published: (2024-02-01) -
A Survey of Pharmacogenomics Testing Among Physicians, Pharmacists, and Researchers From China
by: Chengxian Guo, et al.
Published: (2021-07-01) -
Physicians’ pharmacogenomics information needs and seeking behavior: a study with case vignettes
by: Bret S. E. Heale, et al.
Published: (2017-08-01)